https://www.selleckchem.com/products/mivebresib-abbv-075.html The band gaps are calculated to be 1.3 eV (at +0.2 V/Å), 0.8 eV (at +0.4 V/Å), 0.4 eV (at +0.6 V/Å). Interestingly, the band gap reaches 30 meV at +0.8 V/Å, and with increasr to +0.8 V/Å, a semiconductor-to-metal transition occurs. Furthermore, we investigated effects of semi- and full-hydrogenation of MoS2/C3N and we found that it leads to a metallic and semiconducting character, respectively. The approaches of strain, electric field and hydrogenation are an effective way to tune the band gap and transition of electronic states through band gap control which could lead to potential applications in future nanoelectronic devices. © 2020 IOP Publishing Ltd.Melanoma (MM) is a highly aggressive skin cancer with limited treatment options. Although chemotherapy has been using for advanced melanoma treatment, the lack of targetability, the poor biocompatibility and the severe side effects still hamper the wide applications of chemotherapy agents in MM management. Herein, a biocompatible and biodegradable polymeric hyaluronic acid nanoparticle (HANP) encapsulated with Paclitaxel (PTX) was developed for MM targeted therapy. Our results showed that PTX at 37 ± 2.1% (w/w) was able to be loaded into HANP with over five days of stability under physiological conditions. In vitro, HANP/PTX presented hyaluronidase-dependent drug release. Compared to free PTX, HANP/PTX demonstrated a 6-75 times higher growth inhibition in five different cancer cells, while only presenting minimum toxicity to normal cells. After intravenous administration at a 10 mg/kg equivalent dose of PTX, HANP/PTX significantly ablated MM tumor growth in a mouse model. As confirmed by 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging, the tumors started to respond to the HANP/PTX as early as seven days after the initial treatment, which will significantly benefit for personalized treatment. In conclusion, the HANP/PTX nanoco